NKTR: SEC Form S-8 filed by Nektar Therapeutics
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for NKTR
Across the 26 sessions after earlier NKTR headlines, the stock closed higher 12 times and lower 14 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NKTR | SPY |
|---|---|---|---|
| Oct 12, 2026 | UBS initiated coverage on Nektar Therapeutics with a new price targetand 1 other headline that session | -3.2% | -0.1% |
| Oct 9, 2026 | Raymond James initiated coverage on Nektar Therapeutics | +0.9% | +0.6% |
| Oct 1, 2026 | /UPDATE -- Nektar Therapeutics/and 1 other headline that session | -22.4% | +0.2% |
| Sep 30, 2026 | New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis | +2.2% | -0.2% |
| Sep 28, 2026 | Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026and 1 other headline that session | +5.9% | -0.7% |
| Aug 31, 2026 | Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.6% | -0.3% |
Quantisnow market dataNASDAQ
NKTR
Nektar Therapeutics
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for NKTR
Full NKTR profile on Quantisnow Follow NKTR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time